

Claire Verschraegen, MD, Director  
<http://www.uvm.edu/medicine/medicine/hemonc/>

## **A. Executive Summary**



The Division combines 2 specialties, Hematology and Oncology. There are 2 faculty focusing on benign hematology and thrombosis, 4 faculty treating benign and malignant hematology, 11 medical oncologists, 1 internist (lymphedema), 6 fellows, 3 post-doctoral fellows, 6 midlevel providers, about 70 nurses and staff in the outpatient clinic.

Dr. Eswar Tipirneni started in the fall of 2015 and replaces Dr. Valentine at Central Vermont Medical Center (CVMC). He works with Dr. Ospina, and covers not only CVMC, but also Gifford Hospital in Randolph. Dr. Elvira Umyarova has joined our group in July 2016. She will focus her research and clinical expertise on acute leukemia. She is coming from the University of South Carolina in Charleston.

**PROGRAMS:** The Division supervises

- The Thrombosis & hemostasis Program, (Dr. Cushman, PI)
- The Apheresis Program, (Dr. Sprague, PI)
- The Hemophilia Treatment Center supported by a federal grant, (Dr. Holmes, PI)
- The Stem Cell Transplant Program, which was reaccredited in 2016, (Dr. Sprague, PI)
- The High Risk Breast Program, a clinical research program, (Dr. Wood, PI)
- Cancer Familial Genetics, (Drs. Wood and Greenblatt, PI's)
- Oncology Rehabilitation, (Dr. Dittus, PI)
- Lymphedema Services, (Dr. O'Brien, PI)

Our group embraces the mission of the COM and UVMHC with cost effective high quality care, cutting-edge research, and dedication to all aspects of teaching and research

### **Clinical work**

Clinical efforts for 2016 (pro-rated) include a heavy clinical load with 33,500 outpatient visits (about 2,300 new patients), approximately 12,100 treatment infusion/injection patients and about 7,000 inpatient visits. We are also the attending for patients of local private practices when they are hospitalized at UVMHC. This year, cancer care is being reorganized into the Cancer Service Line, which is a transdisciplinary effort to provide optimal patient-centered care. The Cancer Service Line is organized into Transdisciplinary Academic Teams (TDT), groups of expert physicians and scientists who focus on all aspects of academic medicine for the specific cancers they treat and research. These TDT's are being supported by global services. To name a few, psychiatry and counseling services (Dr. Rabinowitz and 4 psychologists), palliative care (Janet Ely), nutrition, oncology rehabilitation (Dr. Dittus), genetic counseling and other needed services for cancer patients. TDTs' principles include tumor boards, multidisciplinary clinics where at a single visit patients may be seen by a number of oncologic or specialty provider's standardization of clinical care pathways, clinical trial menu and accrual, and education.

Established TDT clinics exist for breast, upper GI, ENT, lung cancer, GU, melanoma, sarcoma, leukemia's and lymphomas. Approximately 674 cases were presented at the TDT clinics. We thank all members of other Divisions for their participation

## **Research**

Research within the Division is done in several collaborative ways (clinical trials, basic science research and epidemiology) covering a number of broad themes (new drug development, cancer treatment and prevention, thrombosis, cardiovascular and stroke epidemiology, supportive care of cancer patients, cancer and exercise, and cancer and coagulation). Working within Transdisciplinary Teams, the faculty of the Hematology/Oncology Division are principal investigators for the majority of the over 200 cancer related studies at the University of Vermont, with 25% of these studies being investigator initiated. Available trials include Phase I-III treatment trials, supportive care and translational studies, with the majority of the later (supportive care and translational studies) being investigator initiated. Investigators within the Division receive funding from clinical trials (cooperative group and pharmaceutical trials), NIH NCI, NHLBI, NINDS and ACS, and through the UVMCC some of the LCCRO funds support Division research activities.

### Publication highlights include

- *Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program*, by Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS (Fam Cancer. 2016);
- *Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers*, by Ho GY, Zheng SL, Cushman M, Perez-Soler R, Kim M, Xue X, Wang T, Schlecht NF, Tinker L, Rohan TE, Wassertheil-Smoller S, Wallace R, Chen C, Xu J, Yu H (J Natl Cancer Inst. 2016);
- *Skeletal muscle fiber size and fiber type distribution in human cancer: Effects of weight loss and relationship to physical function*, by Toth MJ, Callahan DM, Miller MS, Tourville TW, Hackett SB, Couch ME, Dittus K (Clin Nutr. 2016);
- *Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim*, by Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S (Support Care Cancer. 2016).

Dr. Greenblatt is the president of the Human Genome Variation Society.

Dr. Cushman serves on the National Board of Directors of the American Heart Association.

Dr. Wood serves on the American Society of Clinical Oncology CME committee as the liaison to the American Society of Clinical Oncology Prevention Committee and on the Board of the New England Clinical Oncology Society Board, and on the Board of Trustees of the Alliance for Clinical Trials in Oncology

Dr. Ades is the president of the New England Clinical Oncology Society.

Dr. Nunnink serves on the Board of the American Society of Clinical Oncology and is the American Society of Clinical Oncology liaison to the American Medical Association.

Dr. Verschraegen has been appointed on the Board of Directors of the Alliance for Clinical Trials in Oncology and on the National Cancer Institute Gynecologic Cancers Steering Committee.

## **THP**

The Mission of the Thrombosis and Hemostasis Program (THP) is to deliver high quality evidence-based care to patients with venous thromboembolism (VTE), stroke, post-thrombotic syndrome and bleeding disorders, as well as rare disorders. The THP group, including clinicians and clinic staff, meets twice a month to discuss operations, projects and research.

Clinicians working in the program include 3 faculty, Drs. Cushman, Zakai and Holmes, 1 chief medicine resident, Dr. Halevy, 2 hematology oncology fellows doing continuity clinic, 2 nurse practitioners and 2 nurses. There were 740 THP referrals in 2015, an 8.2% increase over 2014. The THP group led or collaborated in over 30 quality improvement project/activities in 2015.

## **New Program to reduce VTE in Patients with Cancer**

This quality initiative program, led by Dr. Chris Holmes, is aimed at preventing venous thromboembolism (VTE) without increasing bleed risk for patients with cancer. This new clinical intervention called VTE-PACC (VTE Prevention in the Ambulatory Cancer Center) was launched by our division, in collaboration with the Jeffords Institute for Quality on October 1, 2015. The program is fully operational and assesses risk for clotting and bleeding for all patients beginning chemotherapy or biologic therapy in the UVM Cancer Center clinic. To date over 300 patients have been assessed. Patients found to be at high risk for VTE are referred to the Thrombosis and Hemostasis Program for follow-up and recommendations. The program involves a team-based approach to educate all patients on their risk of blood clots and tailors VTE prevention treatments to the patient's needs and risks by collaborating with oncologists, hematologists, nursing staff and pharmacists. Of all the patients assessed, 94% have received VTE education, 22% of the patients were found to be high risk of thrombosis and approximately 75% of these were treated prophylactically. To date there have been less than 3% of bleeding adverse events that required holding the preventative anticoagulation. The rate of VTE has declined from 14% to <5% among all patient screened and educated through the program.

## **Hemophilia Treatment Center (HTC)**

The hemophilia treatment center is directed by Dr. Holmes. It is one of 140 federally funded centers offering comprehensive care to patients with hemophilia and other bleeding disorders. The HTC is supported, in part, by two active grants-one from the Centers for Disease Control (CDC) and the other from the Federal Health Resources and Services Administration (HRSA). Annually, the Vermont HTC participates in 4 national surveillance programs; Population Surveillance, American Thrombosis and Hemostasis Network (ATHN) database, Community Counts and Rare Bleeding Disorders. For the first time this year, we participated in a national patient experience survey on transition for pediatric patients. Dr. Holmes sits on the Region 1 Executive Committee, which develops regional and national policies relevant to the care of patients with bleeding disorders. In addition, UVMMC is also now participating in a national program to access transitions of care with Dr. Holmes as the site PI for this multi-institutional quality grant from the ATHN.

## **B. Faculty**

### **Steven Ades, MD, MSc – Associate Professor**

Associate Director, Hematology/Oncology Fellowship Program  
Leader, University of Vermont Medical Center Upper Gastrointestinal Oncology Transdisciplinary Team  
Co-Leader, University of Vermont Medical Center Medical Center Genitourinary Oncology Transdisciplinary Team  
In-Patient Hematology/Oncology Service Director  
Research interests include: GI and GU cancers, supportive care and thrombosis in malignancy

### **George F. Atweh, MD-Professor**

Clinical Director, Cancer Clinical Trials Office  
Member, Protocol Review and Monitoring Committee, UVM Medical Center  
Member, Data Safety Monitoring Board, UVM Cancer Center  
Cabinet Member, Division of Hematology/Oncology  
Research interests include: Molecular basis of benign and malignant blood disorders, and clinical trials in malignant hematology

### **Maura Barry, MD-Assistant Professor**

Associate Director, Hematology/Oncology Fellowship Program  
Research interests include: GI and head and neck cancers

### **Mary Cushman, MD, MSc – Professor, Medicine and Pathology**

Director, Thrombosis and Hemostasis Program  
Research interests include: Etiology of vascular diseases and other chronic diseases; racial disparities; venous thrombosis and post thrombotic syndrome

### **Kim Dittus, MD, PhD – Assistant Professor**

Medical Director of Oncology Rehabilitation  
Chair Research Committee, Program in Integrative Health  
Research interests include: Cancer survivorship, energy balance

### **Edmund Folefac, MD – Assistant Professor**

Research interests include: GI and lung cancers

### **Marc Greenblatt, MD – Professor**

Research interests include: Molecular genetics of mutation in cancer genes and gastrointestinal cancers

### **Chris Holmes, MD, PhD – Associate Professor**

Director, Vermont Regional Hemophilia Treatment Center  
Assistant Director, Thrombosis and Hemostasis Program  
Section Chief, Hematologic Malignancies  
Research interests include venous thrombosis, platelet function, coagulation, and cancer

### **Farrah Khan, MD – Assistant Professor**

Research interests include: Care of patients with breast cancer and lung cancer

### **J. Chris Nunnink, MD, FASCO – Associate Professor**

Attending Physician  
Research interests include: Oropharyngeal Cancer and GU Cancer

### **Patricia O'Brien, MD – Assistant Professor Clinical Scholar**

Director, Lymphedema Program

**Julie Olin, MD – Associate Professor**

Attending Physician

**Julian Sprague, MD, PhD – Assistant Professor**

Director, Hematology/Oncology Fellowship Program

Research interests include: Leukemia and neurotoxicity

**Eswar Tipirneni, MD—Clinical Assistant Professor**

Physician at CVMC

**Claire Verschraegen, MD – Professor**

Director, Hematology/Oncology Division

Co-Director, University of Vermont Cancer Center

Research interests include: Mesothelioma, GYN, Lung and other rare cancers

**Marie Wood, MD – Professor**

Director, Familial Cancer Program

Assistant Director, Hematology/Oncology Division

Medical Director of the Cancer Clinic

Research interests include molecular markers of breast cancer risk, attitudes of primary care physicians regarding cancer genetics, breast cancer screening and prevention

**Neil Zakai, MD, MSc – Associate Professor of Medicine and Pathology**

Research interests include: Epidemiology and novel risk factors for venous thrombosis and cardiovascular disease. Epidemiology, causes, and consequences of anemia in diverse populations. Venous thrombosis causes and prevention, post thrombotic syndrome.

**C. List of Hematology/Oncology Fellows**

Samir Ambrale, MD – 3<sup>rd</sup> year fellow

Inder Lal, MD – 3<sup>rd</sup> year fellow

Hibba Rehman, MD – 2<sup>nd</sup> year fellow

Jose Ruades, MD – 2<sup>nd</sup> year fellow

Bhargavi Pulluri, MD – 1<sup>st</sup> year fellow

Purva Sharma, MD – 1<sup>st</sup> year fellow

**D. List all NP's and PA's**

Jamie Kelly, PA

Penny Gibson, PA

Anne Berkowitz, NP

Janet Ely, NP

Patricia Lewis, NP

Emily Parenteau, MSN, FNP Nurse Practitioner, Thrombosis & Hemostasis Clinic

**E. List all graduate students, post-doctoral fellows, MD PHD students**

Katharine Cheung, MD, Post-Doctoral Associate

Kara Landry, MD, Post-Doctoral

Daniel Douce, MD, Graduate Student, LCCRO Fellow

Elizabeth Hall, MD, Resident Research Project mentored by Neil Zakai

Matthew Lebow, BS, Post-BACC Student

Damon Houghton, MD: Heme/Onc Fellow UNC, mentored by Neil Zakai

## **F. Endowed Professorships**

## **G. Leadership in Professional Societies**

### **Steven Ades, MD**

Member, UVM Faculty Senate Financial & Physical Planning Committee  
Member, UVM Surgical Oncology Faculty Search Committee  
Associate Program Director, Hematology Oncology Fellowship Program  
Member, UVM Medical Center Hematology/Oncology Fellowship Program Evaluation Committee  
Member, UVM Medical Center Hematology/Oncology Fellowship Clinical Competency Committee  
Member, Vermont Cancer Center Protocol Review and Monitoring Committee  
President, Northern New England Clinical Oncology Society  
Member, Alliance Symptom Intervention Committee

### **Maura Barry, MD**

Member, UVM Medical Center Faculty Development Committee,  
Member, UVM Medical Center Hematology/Oncology Fellowship Program Evaluation Committee  
Member, UVM Internal Medicine Residency Program Evaluation Committee  
Member, UVM Medical Center Hematology/Oncology Fellowship Clinical Competency Committee

### **Mary Cushman, MD, MSc**

Member, Scientific Program Planning Committee, World Heart Federation and American Board Director, American Heart Association  
Member of the American Society of Hematology Media Experts Subcommittee.  
Member, Program Committee for Venous thrombosis Disorders, International Society on Thrombosis and Haemostasis 2015 Congress, Toronto.  
Board Director, North American Thrombosis and Hemostasis Society  
President, Board of Directors Vermont District, American Heart Association  
Member, Medical Alumni Executive Committee  
Member, Volunteer Oversight Group, American Heart Association  
Member, Quality Committee, American Society of Hematology  
Member, Media Experts Committee, American Society of Hematology  
Member, Statistics Committee, American Heart Association  
Member, Corporate Relations Review Committee  
Member, ASH Maintenance of Certification Committee

### **Kim Dittus, MD, PhD**

Member, Protocol Review Committee, UVM Cancer Center  
Member, Cancer Control Committee, UVM Medical Center  
Member, Champlain Valley Healthy Lifestyle Collaborative  
Member, Symptom Intervention Committee, Alliance

**Marc Greenblatt, MD**

Member, American Association of Cancer Research  
Member, American Society of Clinical Oncology  
Member, American Society of Human Genetics  
Member, Collaborative Group of the Americas on Inherited Colorectal Cancer  
Member, International Society for Gastrointestinal Hereditary Tumors (InSiGHT)  
Member, Human Genome Organization Mutation Database Initiative  
Member, Human Genome Variation Society  
Member, Human Variome Project (HVP)  
Member, International Mismatch Repair Consortium (IMRC)  
Member, Cancer and Leukemia Group B- Alliance for Clinical Trials  
Member, National Surgical Adjuvant Breast Program  
Member, Vermont Medical Society  
Co-Chair, Working Group on Assessment of Pathogenicity, Human Variome Project  
Core Member, Variant Interpretation Committee, International Society for Gastrointestinal Hereditary Tumors (InSiGHT)  
Co-Chair, Working Group on Assessment of Pathogenicity, Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC)  
Member, Scientific Advisory Council, Human Variome Project  
Present, Human Genome Variation Society (HGVS)

**Chris Holmes, MD, PhD**

Member, Thrombosis Committee, American Thrombosis and Hemostasis Network, Centers for Disease Control  
National Chair, Hemophilia Transitions, American Society of Hematology Workgroup on Transitions; American College of Physicians Pediatric to Adult Care Transition Initiative  
Executive Board Member, National Network, Health and Human Services New England Comprehensive Hemophilia Diagnostic and Treatment Centers  
Director, Community Counts-Vermont, Centers for Disease Control (CDC) Public Health Monitoring Program, Division of Blood Disorders  
Member, Institutional Review Board, Committee on Human Research in the Medical Sciences (CHRMS), University of Vermont

**Farrah Khan, MD**

Chair, Breast Research Meeting  
Member: UVMMC Department of Medicine Faculty Development Committee, Faculty Engagement Committee  
Member, UVMMC Department of Medicine Quality Assurance and Improvement Committee

**J. Chris Nunnink MD, FASCO**

Member, UVM Medical Center Clinical Integration Committee  
Member, UVM Medical Center CIC Committee representing Oncology  
Co-Chair, UVM Medical Center Head and Neck Multidisciplinary Clinic  
Director, UVM Cancer Center Network Development

Member, American Society of Clinical Oncology Board of Directors  
Member, American Society of Clinical Oncology Strategic Planning Committee  
Member, American Society of Clinical Oncology Clinical Guidelines Committee  
Member, Northern New England Clinical Oncology Society Board of Directors

**Julian Sprague, MD**

Member, UVM Medical Center, Transfusion Committee  
Member, UVM Medical Center, Ethics Committee  
Member, UVM Medical Center, Medical School Curriculum Committee  
Member, American Society of Hematology  
Member, American Society of Clinical Oncology  
Member, American College of Physicians

**Claire Verschraegen, MD**

Member, ACS New England Cancer Director's Roundtable, Boston, MA, Conference Committee  
Member, NCI Gynecological Cancers Steering Committee, SWOG representative  
Board of Directors Alliance for Clinical Trials in Oncology  
Member, NCI Uterine Cancer Task Force Member, SWOG representative  
Member, SWOG Rare Cancers Task Force  
Member, Vermonters Taking Action Against Cancer (VTAAC) –Steering Committee  
Member, SWOG Early Therapeutics Committee  
Member, SWOG Lung Cancer Committee  
Member, SWOG Cancer Control and Prevention Committee  
Member, Connective Tissue Oncology Society  
Member, American College of Physicians  
Board of Director, Alliance for Clinical Trials in Oncology  
Board of Director, National Cancer Institute Gynecologic Cancers Steering Committee

**Marie Wood, MD**

Member, Alliance, Prevention Committee  
Member, Alliance Foundation, Board of Trustees  
Member, American Society of Clinical Oncology, CME Committee  
Member, Northern New England Clinical Oncology Society Board of Directors  
Member, American College of Physicians  
Member, National Surgical Adjuvant Breast and Bowel Project

**Neil Zakai, MD**

Member, American Heart Association, Disparities Research Network Peer Review Committee  
Member, American Society of Hematology VTE Guideline Panel: Prevention of VTE in Medical Patients  
Co-Chair, Hemophilia and Thrombosis Research Society, Research Committee  
Vice Chair, American Heart Association Council on Epidemiology and Prevention, Publications Committee



Member, American Society of Hematology “Consult a Colleague” program-content expert “Hemostasis/Thrombosis”  
Member, American Heart Association Representative to the American Association of Blood Banks: Blood Banks and Transfusion Services Standards Program Unit  
Member, American Heart Association POP 2 Peer Review Committee  
Member, Hemophilia and Thrombosis Research Society Membership Committee  
Coordinator, Hematology/Oncology Fellowship Quality Project Committee  
Member, UVM Medical Center Hematology/Oncology Fellowship Research Committee  
Member, UVM Medical Center Internal Medicine Residency Committee  
Guest Editor, Circulation

#### **H. Editorships and Editorial Boards**

**Neil Zakai**

Guest Editor, Circulation

#### **I. Study Sections and Federal Advisory Boards**

**Clair Verschraegen**

NCI Special Emphasis Panel

NCIC Review Section

#### **J. Major Faculty Awards**

#### **K. Grants**

##### **George Atweh**

NIHU01 HL117709

Punam, Malik (PI)

08/15/13-05/31/18

Cincinnati Center Excellence in Hemoglobinopathies Research

Role: Co-Investigator

##### **Maura Barry**

University of Vermont Medical Center Foundation

12/1/15-12/1/17

Victoria Buffum Endowment

Quality of Life Assessment for Head and Neck Cancer Patients Undergoing Treatment in

The First Year of Survivorship

Role: PI

##### **Mary Cushman**

NINDS

08/01/02-11/30/17

U01 NS041588

Etiology of Geographic and Racial Differences in Stroke

Mortality

G Howard, PI, University of Alabama at Birmingham

ADC (current Vermont subcontract): \$684,296

Role: Subcontract PI, 20%

NHLBI 01/01/98-03/31/17  
R01 HL59367  
Epidemiology of Venous Thrombosis and Pulmonary Embolism  
AR Folsom, PI, University of Minnesota  
ADC (current Vermont Contract): \$33,723  
Role: Subcontract PI, 10%

NHLBI 08/15/00-08/14/21  
HHSN2682015000031  
Multiethnic Study of Atherosclerosis  
R. McClelland, PI, University of Washington  
ADC (current Vermont Subcontract): \$92,375 (current cycle)  
Role: Subcontract PI, 5%

NIH 07/01/14-06/30/19  
P01HD03192116A1  
The National Longitudinal Study of Adolescent Health - Wave V  
ADC: (Vermont Subcontract): \$478,373  
K Harris, PI; University of North Carolina, Chapel Hill  
ADC: (Vermont Subcontract): \$478,373  
Role: Subcontract PI, 10%

NIH 09/08/14-05/30/19  
P20GM109098  
Effects of Perfluoroalkyl Chemicals on Stroke Incidence and Mortality  
S Frisbee, PI  
ADC (Subcontract): \$6,978  
Role: Subcontract, PI, 2%

NIH 04/01/16-03/31/21  
NICHD  
Social Context, Life Course and Genetic Transcription in Add Health  
ADC (subcontract): \$23,489  
Role: Subcontract PI, 2.5%

NIH 06/01/16-05/31/21  
Transitions to Family Caregiving and its Impact on Health Indicators  
ADC: \$75,466  
Role: Co-Investigator, 5%

**Kim Dittus**

NIH-NIGMS Higgins (PI) 9/15/13-7/31/18  
1P20GM103644-01A1  
Vermont Center on Behavior and Health, COBRE  
Junior Investigator Project: Predictors of Weight Loss Success in  
Overweight Breast Cancer Survivors



PI: G Howard, University of Alabama at Birmingham  
Role: Co-investigator 10%

## **L. Publications**

Lanktree MB, Elbers CC, Li Y, Zhang G, Duan Q, Karczewski KJ, Guo Y, Tragante V, North KE, **Cushman M**, Asselbergs FW, Wilson JG, Lange LA, Drenos F, Reiner AP, Barnes MR, Keating BJ. Genetic Meta-Analysis of 14,901 African Americans Identifies Variation in EXOC3L1 is Associated with HDL Concentration. *J Lipid Res* 2015 Jul pii: jlr P059477 (Epub ahead of print) PMID: 26199122

Gunter MJ, Wang T, **Cushman M**, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer. *J Natl Cancer Inst.* 2015 Jul 16;107(9). pii:djv169. Doi: 10.1093/jnci/djv169. Print 2015 Sep. PMID: 26185195

Ho GY, Zheng SL, **Cushman M**, Perez-Soler R, Kim M, Xue X, Wang T, Schlecht NF, Tinker L, Rohan TE, Wassertheil-Smoller S, Wallace R, Chen C, Xu J, Yu H. Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers. *J Natl Cancer Inst* 2016 Apr 12;108-(7) pii: djw012. doi: 10.1093/jnci/djw012. PMID: 27071409

Ji Y, Schwartz J, Ramsey J, Phillips J, **Verschraegen C**. Successful Treatment of Non-Small Cell Lung Cancer with Erlotinib Throughout Pregnancy. *JAMA Oncol.* 2015 July 9. doi: 10.1001/jamaoncol.2015.1300

Engbers MJ, Karasu A, Blom JW, **Cushman M**, Rosendaal FR, van Hylckama Vlieg A. Br. Clinical Features of Venous Insufficiency and the Risk of Venous Thrombosis in Older People. *J Haematol.* 2015 Jul 27. doi: 10.1111/bjh.13579. (Epub ahead of print) PMID: 26221838

Olson NC, Butenas S, Lange, LA, Lange, EM, **Cushman, M**, Jenny NS, Walston J, Souto JC, Soria JM, Chauhan G, Debette S, Longstreth WT, Seshadri S, Reiner AP, Tracy RP. Coagulation Factor XII Genetic Variation, Ex Vivo Thrombin Generation and Stroke Risk in the Elderly: Results from the Cardiovascular Health Study. *J Thromb Haemost.* 2015 Aug 19. doi: 10.1111/jth.13111 (Epub ahead of print) PMID: 26286125

Folsom AR, Tang W, Roetker NS, Heckbert SR, **Cushman M**, Pankow JS. Prospective Study of Circulating Factor XI and Incident Venous Thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) *Am J Hematol.* 2015 Aug 11. doi: 10.1002/ajh.24168. (Epub ahead of print) PMID: 26260105

Durda P, Sabourin J, Lange EM, Nalls MA, Mychalecky JC, Jenny NS, Li J, Walston J, Harris TB, Patsy BM, Valdar W, Liu Y, **Cushman M**, Reiner AP, Tracy RP, Lange LA. Genomoe-Plasma Levels of Soluble IL-2 Receptor A: Associations with Clinical Cardiovascular Events and Wide Association Scan. *Arterioscler Thromb Vasc Biol.* 2015 Aug 20. pii: ATVBAHA.115.305289 (Epub ahead of print) PMID: 26293465

Bingham N, Wallace III HJ, Monterroso J, **Verschraegen C**, Waters BL, Anker CJ. Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation Therapy. *Case Rep Oncol Med*. 2015 Oct ; 2015:513685 PMID: 26634162

Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, **Verschraegen C**. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. *J Clin Oncol*. 2015 Dec 1; 33(34):4093-8. doi: 10.1200/JCO.2015.61.6490 PMID: 26527781

Schott AF, Welch JJ, **Verschraegen CF**, Kurzrock R. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. *Semin Oncol*. 2015 Oct;42(5):731-9. doi: 10.1053/j.seminoncol.2015.07.010 PMID: 26433554

Bell EJ, Folsom AR, Lutsey PL, Selvin E, **Zakai NA**, **Cushman M**, Alonso A. Diabetes Mellitus and Venous Thromboembolism: A Systematic Review and Meta-Analysis. *Diabetes Res Clin Pract*. 2015 Nov 10. pii: S0168-8227(15)00420-9. doi: 10.1016/j.diabres.2015.10.019 (Epub ahead of print) PMID: 26612139

Huffman JE, deVries PS, Morrison AC, Sabater-Lleal M, Kacprowski T, Auer PL, **Cushman M**, Reiner AP, O'Donnell CJ, Smith NL. Rare and Low-Frequency Variants and their Association with Plasma Levels of Fibrinogen FVII, FVIII and vWF. *Blood* 2015;126:e19-29. PMID: 26105150

Peralta CA, Muntner P, Scherzer R, Judd S, **Cushman M**, Shlipak MG. A Risk Score to Guide Cystatin C Testing to Detect Occult Reduced Estimated Glomerular Filtration Rate. *Am J Nephrol* 2015; 42:141-7. PMID: 26381887

Gunter MJ, Wang T, **Cushman M**, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. *J Natl Cancer Inst* 2015;107:djv169. PMID: 26185195

O'Neal WT, Soliman EZ, Howard G, Howard VJ, Safford MM, **Cushman M**, **Zakai NA**. Inflammation and Hemostasis in Atrial Fibrillation and Coronary Heart Disease. The Reasons for Geographic and Racial Differences in Stroke Study. *Atherosclerosis* 2015;243:192-7 PMID: 26398291

Folsom AR, Alonso A, George KM, Roetker NS, Tang W, **Cushman M**. Prospective Study of Plasma D-Dimer and Incident Venous Thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. *Thromb Res* 2015;136:781-5 PMID: 26337932

Olson NC, Butenas S, Lange E, Lange LA, Jenny NS, Walston J, **Cushman M**, Tracy RP, Reiner AP. Coagulation Factor XII Genetic Variation Ex Vivo Thrombin Generation and Stroke

Risk in the Elderly: Results from the Cardiovascular Health Study. *J Thromb Haemost* 2015;13:1867-77 PMID: 26286125

Folsom AR, Tang W, Roetker NS, Heckbert SR, **Cushman M**, Pankow JS. Prospective Study of Circulating factor XI and Incident Venous Thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). *Am J Hematol* 2015;90:1047-51. PMID: 26260105

Durda P, Sabourin J, Lange EM, Nalls MA, Mychaleckyi JC, Jenny NS, Li J, Walston J, Harris TB, Psaty BM, Valdar W, Liu Y, **Cushman M**, Reiner AP, Tracy RP, Lange LA. Plasma Levels of Soluble Interleukin-2 Receptor  $\alpha$ : Associations with Clinical Cardiovascular Events and Genome-Wide Association Scan. *Arterioscler Thromb Vasc Biol* 2015;35:2246-53. PMID: 26293465

Winters JP, Callas PW, **Cushman M**, Repp AB, **Zakai NA**. Central Venous Catheters and Upper Extremity Deep Vein Thrombosis in Medical Inpatients: the Medical Inpatients and Thrombosis (MITH) Study. *J Thromb Haemost*. 2015 Dec; 13:2155-60. PMID: 26340226

Huffman JE, de Vries PS, Morrison AC, Sabater-Lleal M, Kacprowski T, Auer PL, Brody JA, Chasman DI, Chen MH, Guo X, Lin LA, Marioni RE, Muller-Nurasyid M, Yanek LR, Pankratz N, Grove ML, de Maat MP, **Cushman M**, Wiggins KL, Qi L, et al. Rare and Low-Frequency Variants and their Association with Plasma Levels of Fibrinogen, FVII, FVIII, and vWF. *Blood* 2015 Sep 10;126(11):e19-29. PMID: 26105150

Daniels LB, Clopton P, Defilippi CR, Sanchez O, Bahrami H, Lima JAC, Tracy RP, Siscovick D, Bertoni AG, Greenland P, **Cushman M**, Maisel AS, Criqui MH. Serial Measurement of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T for Cardiovascular Disease Risk Assessment in the Multi-Ethnic Study of Atherosclerosis. *Am Heart J*. 2015 Dec;170(6):1170-83. PMID: 26678639

Folsom AR, Tang W, Weng LC, Roetker NS, **Cushman M**, Basu S, Pankow JS. Replication of Genetic Risk Score for Venous Thromboembolism in Whites but not in African Americans. *J Thromb Haemost* 2016 Jan; 14(1):83-8. doi:10.1111/jth.13193

Oetting WS, Brenner SE, Brookes AJ, **Greenblatt MS**, Hart RK, Karchin R, Sunyaev SR, Taschner PE. Pathogenicity Interpretation in the Age of Precision Medicine: The 2015 Annual Scientific Meeting of the Human Genome Variation Society. *Hum Mutat*. 2016 Apr; 37(4):406-11. doi: 10.1002/humu.22958 PMID: 26791113

Moukharskaya J, Abrams DM, Ashikaga T, **Khan F**, Schwartz J, Wilson K, **Verschraegen C**, Openshaw T, Valentine J, Eneman J, Unger P, **Ades S**. Randomized Phase II Study of Loratadine for the Prevention of Bone Pain Caused by Pegfilgrastim. *Support Care Cancer*. Epub 2016 Feb 19 PMID: 26894485

**Cushman M**, O'Meara ES, Heckbert SR, **Zakai NA**, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. *Thromb Res*. 2016 Jun 15;144:127-132 doi: 10.1016/j.thromres.2016.06.012 PMID: 27328432

Larson N, Bell E, Decker P, Pike M, Wassel C, Tsai M, Pankow J, Tang W, Hanson N, Alexander K, **Zakai NA**, **Cushman M**, Bielinski S. ABO blood group associations with markers of endothelial dysfunction in the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2016 Jun 7 pii: S0021-9150(16)30226-X doi: 10.1016/j.atherosclerosis.2016.05.049(PubMed-in process)

Jones C, Fernandez L, Weimersheimer P, **Zakai NA**, Sharf M, Meso O, Peters C, di Carlo A, Norotsky M. Estimating the burden of cost in chronic graft-versus-host disease: A Human Capital Approach. *Journal of Health Economics and Outcomes Research* 2016;4(2):113-8. (PubMed – in process)

Shiyanbola OO, Sprague BL, Hampton JM, **Dittus K**, James TA, Herschorn S, Gagnon RE, Weaver DL, Trentham-Dietz A. Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. *Cancer* 2016 May 31. doi: 10.1002/cncr.30105. PMID: 27244699

Savage PD, **Dittus K**, Lakoski SG. Fitness during breast cancer treatment and recovery in an athlete: A Case Study. *Med Sci Sports Exerc*. 2016 May 17 (Epub ahead of print) PMID: 27187100

Toth MJ, Callahan DM, Miller MS, Tourville TW, Hackett SB, Couch ME, **Dittus K**. Skeletal muscle fiber size and fiber type distribution in human cancer: Effects of weight loss and relationship to physical function. *Clin Nutr* 2016 Mar 8 pii: S0261-5614(16) 00087-X doi: 10.1016/j.clnu.2016.02.016 PMID: 27010836

Den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, **Greenblatt MS**, McGowan-Jordan J, Roux AF, Smith T, Antonarakis SE, Taschner PE. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. *Hum Mutat* 2016 Jun;37(6):564-9 doi: 10.1002/humu.22981 PMID: 26931183

Oetting WS, Brenner SE, Brookes AJ, **Greenblatt MS**, Hart RK, Karchin R, Sunyaev SR, Taschner PE. Pathogenicity Interpretation in the Age of Precision Medicine: The 2015 Annual Scientific Meeting of the Human Genome Variation Society. *Hum Mutat* 2016 Apr;37(4):406-11 doi: 10.1002/humu.22958 PMID: 2679113

**Greenblatt MS**, Sequence variants of uncertain significance: What to do when genetic test results are not definitive *Surg Oncol Clin N Am*. 2015 Oct;24(4):833-46 doi: 10.1016/j.soc.2015.06/009 PMID: 26363543

Waheed W, Varigonda AL, **Holmes CE**, Trevino C, Borden NM, Pendlebury W. Spinal cord infarction in a patient with hereditary spherocytosis: A case report and discussion. *Case Rep Neurol Med* 2016;2016:7024120 doi: 10.1155/2016/7024120 PMID: 27051541

Schneider DJ, **Holmes CE**, Levis JE, Bambace N, Sharma D, Lal I, **Wood ME**, Muss HB. Platelet phenotype changes associated with breast cancer and its treatment, *Platelets* 2016; doi:10.3109/09537104.2016.1171302. PMID: 27135253

**Wood ME**. Family history matters. *Cancer* 2016 Jun 3 doi: 10.1002/cncr.30078 PMID: 27258002

Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, Muss HB, Garber Je, **Wood ME**, The Effect of Atorvastatin on breast cancer biomarkers in high-risk women. *Cancer Prev Res (Phila)* 2016 May;9(5):379-84 doi:10.1158/1940-6207. CAPR-15-0300 PMID: 26908565

Farina NH, Ramsey JE, Zingiryan Z, **Ades S**, Plante MK, Stein GS, Stein JL, Lian JB, Perrapato SD, Serum miRNAs associated with prostate cancer: correlation to deregulated signaling pathways. *Cancer Research*, 2015.75(15 Supplement):p.4003-4003

O'Toole, J, **Ades S**, Waters B, Agarwal Z, Lamba G. Delayed HHV-6 encephalitis in an allogeneic stem cell transplant patient. *Leukemia and Lymphoma*, 2015: p. 1-8

Pun SC, Nguyen A, **Ades S**, Storrington J, Ingrid H, Sebag M, Huynh T. Predictive value of high-sensitivity cardiac troponin T, troponin I, NT-proBNP and high-sensitivity CRP in the detection of myocardial injury following anthracycline-based chemotherapy. *Journal of the American College of Cardiology*, 2015. 65(10\_S)

Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS, Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. *Fam Cancer* 2016 (Epub ahead of print) PMID: 27401692